Besides ibrutinib, patients with M-CLL, devoid of TP53 aberrations and suit plenty of to tolerate FCR therapy, may still be good candidates to the latter, Together with the benefit staying that this cure may be done in six months even though ibrutinib have to be taken indefinitely. This feature coul